We have strategic partnerships through which we can broadly expand our drug discovery efforts to new disease targets in specific therapeutic areas. Our partners provide expertise, tools and resources to complement our drug discovery efforts. We have established strategic partnerships with the following pharmaceutical industry leaders:
- Biogen: We have a broad strategic collaboration with Biogen to discover and develop antisense drugs to treat neurological diseases. To date, our collaboration with Biogen has produced SPINRAZA, the first and only approved treatment for patients with spinal muscular atrophy, as well as two antisense drug candidates in the clinic, with the potential to advance up to seven more drug candidates within the next two years. SPINRAZA is approved in global markets to treat patients with spinal muscular atrophy. Biogen licensed the global rights to develop, manufacture and commercialize SPINRAZA from us in August 2016 and is now responsible for all development, regulatory and commercialization activities and costs for SPINRAZA. For complete SPINRAZA U.S. prescribing information please visit www.SPINRAZA.com. In April 2018, we and Biogen expanded our collaboration to discover and develop antisense drugs for a broad range of neurological diseases through a new ten-year collaboration agreement, which capitalizes on Biogen’s expertise in neuroscience research and drug development and Ionis’ leadership in RNA targeted therapies. For more information about our collaboration with Biogen, see the announcement here.
- AstraZeneca: We have a broad collaboration with AstraZeneca, under which AstraZeneca is developing five drugs, including three drugs under a collaboration to discover and develop antisense drugs to treat cardiovascular, renal and metabolic diseases, and two drugs under a collaboration to discover and develop antisense drugs targeting a small number of specified targets to treat cancer. In 2018, AstraZeneca licensed both IONIS-AZ6-2.5-LRx to inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis (NASH) (see the announcement here) and IONIS-AZ5-2.5Rx to inhibit an undisclosed target to treat patients with a genetically associated form of kidney disease (see the announcement here). In 2016, AstraZeneca selected for development IONIS-AZ4-2.5-LRx to inhibit an undisclosed target to treat cardiovascular disease (see the announcement here) and licensed IONIS-KRAS-2.5Rx and will advance it in development for the treatment of cancer (see the announcement here). We and AstraZeneca are also developing danvatirsen (IONIS-STAT3-2.5Rx) for the treatment of cancer (see the announcement here).
Research, Development and Commercialization Partners
We have partnerships with companies that bring significant expertise and global resources to develop and commercialize, if approved, drugs for a particular therapeutic area. These partnerships often enable us to accelerate the development of our drugs for broader patient populations in which late-stage development would be costly and complex. We have established the following research, development and commercialization partnerships:
- Bayer: We have an exclusive license agreement with Bayer for the development and commercialization of two antithrombotic drugs that target Factor XI for the treatment of patients at risk for thrombosis. Bayer is advancing both IONIS-FXIRx and IONIS-FXI-LRx, which utilizes Ionis’ LICA technology. For additional information about this collaboration, please see the announcement here.
- GSK: We have an alliance with GSK to discover and develop new drugs to treat patients with hepatitis B virus infection, a serious health problem that can lead to significant and potentially fatal health conditions, including cirrhosis, liver failure and liver cancer. Our alliance with GSK is comprised of two drugs: IONIS-HBVRx and IONIS-HBV-LRx, both designed to reduce the production of viral proteins associated with HBV infection.
- Janssen: We have an alliance with Janssen to discover and develop antisense drugs to treat autoimmune disorders in the GI tract. Under this agreement, Janssen has licensed IONIS-JBI1-2.5Rx and IONIS-JBI2-2.5Rx to treat patients with gastrointestinal autoimmune disease. For additional information about this collaboration, please see the announcements here and here.
- Novartis: We and Akcea initiated a collaboration with Novartis in 2017 to develop and co-commercialize AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for the treatment of patients at high cardiovascular risk due to inadequately treated lipid disorders. After we and Akcea complete Phase 2 development of each drug, Novartis may exercise its option to license the drug. For additional information about this collaboration, please see the announcement here.
- Roche: We have an alliance with Roche to discover and develop antisense drugs to treat Huntington’s disease (HD). In December 2017, we reported that Roche licensed IONIS-HTTRx following successful completion of a Phase 1/2a study in patients with early manifest HD. Upon licensing, Roche assumed responsibility for all development and commercial activities. For additional information about this collaboration, please see the announcement here.
Additional information on our various partners is available in our annual report, which is on file with the SEC.